HMI HOUSTON MEDICAL IMAGING
A Tradition of Excellence In Patient Care

Phone: 713.589.5231
Fax: 713 383 9933
www.hmixray.com

ACR AMERICAN COLLEGE OF RADIOLOGY ACCREDITED FACILITY

PATIENT INFORMATION

Patient Name: _____

Date of Birth: _____

Cell Phone: _____

Authorization #: _____

Referral #: _____

Insurance: _____

Policy ID #: _____ Group: _____

Secondary Insurance: _____

Policy ID #: _____ Group: _____

REQUESTING PHYSICIAN INFORMATION

Fax Report: (Fax#): _____

Phone Report: (Phone#): _____

Referring Pysician: _____
(Please print)

Referring Physician Signature: _____

CD with images ○ STAT ○ Please call Patient ○

Procedures:

○ 78814-Q9983 PET CT BRAIN NEURACEQ
○ 78814-A9586 PET CT BRAIN AMYVID

ICD-10 national coverage are the following:

○ **F03.90:** Unspecified dementia without behavioral disturbance
○ **F03.90 plus F05:** Unspecified dementia without behavioral disturbance and Delirium not superimposed on dementia, so described
○ **G30.9:** Alzheimer´s disease, unspecified
○ **G31.9:** Other frontotemporal dementia
○ **R41.2 or R41.3:** Retrograde amnesia or Other amnesia (amnesia NOS, memory loss NOS)
○ **G30.0** Alzheimer's disease (AD) with early onset
○ **G30.1** Alzheimer's disease (AD) late onset
○ **G30.8** Other Alzheimer's disease
○ **G31.84** Mild cognitive impairment of uncertain or unknown etiology

The following requirements must be included in clinical.

- Date of onset of symptoms
- Diagnosis of clinical syndrome (normal aging, mild cognitive impairment or MCI: mild, moderate, or severe dementia)
- Mini mental status exam (MMSE) or similar test score
- Presumptive cause (possible, probably, uncertain AD)
- Any neuropsychological testing performed
- Results of any structural previous imaging (MRI, CT) performed
- Current treatments/medications being used for the outlined symptoms

Amyloid PET scan [including, but not limited to, florbetapir F18 (Amyvid), florbetaben F18 (Neuraceq) reasonable and medically necessary for members with a clinical diagnosis of mild cognitive impairment **due to Alzheimer disease or mild Alzheimer Dementia who are being considered for enrollment in a clinical trial/registry of Food and Drug Administration (FDA) approved monoclonal antibodies**